The Interplay between the Renin Angiotensin System and Pacing Postconditioning Induced Cardiac Protection

Fawzi Babiker1*, Aishah Al-Jarallah2, Shaji Joseph1

1 Departments of Physiology, Faculty of Medicine, Health Science Center, Kuwait University, Jabriya, Kuwait
2 Department of Biochemistry, Faculty of Medicine, Health Science Center, Kuwait University, Jabriya, Kuwait

* Fawzi.b@hsc.edu.kw

Abstract

Background
Accumulating evidence suggests a cardioprotective role of pacing postconditioning (PPC) maneuvers in animal models and more recently in humans. The procedure however remains to be optimized and its interaction with physiological systems remains to be further explored. The renin angiotensin system (RAS) plays a dual role in ischemia/reperfusion (I/R) injury. The interaction between RAS and PPC induced cardiac protection is however not clearly understood. We have recently demonstrated that angiotensin (1–7) via Mas receptor played a significant role in PPC mediated cardiac protection against I/R injury.

Objective
The objective of this study was to investigate the role of angiotensin converting enzyme (ACE)—chymase—angiotensin II (Ang II)—angiotensin receptor 1 (AT1) axes of RAS in PPC mediated cardiac protection.

Methods
Isolated rat hearts were subjected to I/R (control) or PPC in the presence or absence of Ang II, chymostatin (inhibitor of locally produced Ang II), ACE blocker (captopril) or AT1 antagonist (irbesartan). Hemodynamics data was computed digitally and infarct size was determined histologically using TTC staining and biochemically by measuring creatine kinase (CK) and lactate dehydrogenase levels.

Results
Cardiac hemodynamics were significantly (P<0.001) improved and infarct size and cardiac enzymes were significantly (P<0.001) reduced in hearts subjected to PPC relative to hearts subjected to I/R injury. Exogenous administration of Ang II did not affect I/R injury or PPC mediated protection. Nonetheless inhibition of endogenously synthesized Ang II protected against I/R induced cardiac damage yet did not block or augment the protective effects of
PPC. The administration of AT1 antagonist did not alleviate I/R induced damage. Interestingly it abrogated PPC induced cardiac protection in isolated rat hearts. Finally, PPC induced protection and blockade of locally produced Ang II involved enhanced activation of ERK1/2 and Akt components of the reperfusion injury salvage kinase (RISK) pathway.

Conclusions
This study demonstrate a novel role of endogenously produced Ang II in mediating I/R injury and highlights the significance of AT1 signaling in PPC mediated cardiac protection in isolated rodents hearts ex vivo. The interaction between Ang II-AT1 and PPC appears to involve alterations in the activation state of ERK1/2 and Akt components of the RISK pathway.

Introduction
Cardiovascular diseases are major health concerns worldwide and coronary heart disease (CHD) continues to be a leading cause of death [1]. Intermittent interruption of coronary flow in the early phases of reperfusion, postconditioning, has proven to be cardioprotective [2]. Recently however well planned postconditioning clinical studies resulted in disappointing negative outcomes [3–6] thus necessitating the requirement of alternative procedures that can successfully be translated to the clinic [7]. Pacing post conditioning (PPC) is a modification of classical ischemic postconditioning that involves changing the stretch pattern of the heart by intermittent dyssynchrony of the left ventricle (LV) contraction at a remote site away from the affected blood vessel [8]. We have previously demonstrated a pronounced reduction in the infarct size and a significant improvement in cardiac hemodynamics in hearts subjected to PPC [9, 10]. Recent introduction of PPC to the clinic demonstrated promising results in ST-segment elevation myocardial infarction (MI) patients [11]. When combined with percutaneous coronary intervention, PPC consisting of 10 episodes of 30 sec right ventricle pacing resulted in a 25% reduction in infarct size [11]. Despite the observed cardioprotection PPC however, resulted in an increased incidence of ventricular fibrillation and paroxysmal atrial fibrillation [11]. This could be due to prolonged pacing as continuous prolonged pacing was proven to be detrimental to the heart [12]. PPC thus appears to be a potentially attractive target. However optimization of PPC maneuver and in depth understanding of its interaction with potentially relevant physiological mediators are challenges that remain to be addressed for an appropriate application of the technique in the clinic.

The renin-angiotensin system (RAS) is a master regulator of cardiovascular physiology and remodeling [13]. Key effector peptides of the RAS include angiotensin II (Ang II) and angiotensin (1–7) acting via angiotensin receptors-1 or -2 (AT1 or AT2) and Mas receptors, respectively [14]. While Ang II generally demonstrated to have detrimental effects on the development and progression of cardiovascular disease [15–17], Ang (1–7) was shown to be protective [18]. The exact role of RAS in PPC mediated protection is however not well defined. We have recently demonstrated the involvement of Ang (1–7)-Mas receptor axes in the cardioprotective effects of PPC in isolated rodent hearts [18]. In this study however we were set to determine the role of the other arm of the RAS, specifically Ang II, in PPC mediated cardiac protection. Ang II is a biologically active octapeptide that can be produced systemically by the action of angiotensin converting enzyme (ACE) on circulating angiotensinogen [13] or locally via ACE dependent
Evidence from clinical studies indicate enhanced chymase activity relative to other Ang II forming enzymes including ACE and cathapsin G in the myocardium 14–21 days post myocardial infarction (MI) suggesting the importance of chymase in post ischemic damage to cardiomyocytes [22]. The role of systemically produced or endogenously synthesized Ang II in PPC mediated protection is however not clearly understood. We hypothesize that exogenously infused and/or locally produced Ang II, acting via AT1, to negatively impact PPC mediated cardiac protection. The objective of this study was therefore to investigate the involvement of ACE-chymase-Ang II-AT1 axes in PPC mediated cardiac protection and map potential downstream signaling pathways.

Material and Methods

Materials

All chemicals used in this study were purchased from Sigma Aldrich (Sigma–Aldrich, St. Louis, Missouri) unless otherwise indicated. The following drugs were used in the study and drug doses were selected based on previously published studies: Ang II (100nM) [23], AT1 blocker (irbesartan, 10 μM) [24], chymase inhibitor (chymostatin, 100 nM) [25] and ACE inhibitor (captopril, 100 μM) [26]. All drugs were dissolved in the perfusion buffer.

Ethics statement

The study was approved by Health Science Center, Kuwait University Ethics Committee for animal use. The study was conducted according to the laboratory’s animal care guidelines at Kuwait University, Kuwait in accordance with the international standards of animal care. Rats were maintained at 22°C on 12-hr light/dark cycle (7 am– 7 pm) and water and food were available ad libitum. Rats were anesthetized with intraperitoneal injection of sodium pentobarbital (60 mg/kg) and heparin (1000 U/kg) was administered through the femoral vein, then were sacrificed by cervical dislocation.

Animals and Instrumentation

Hearts isolated from male Wistar rats weighing between 270–300 g were used for this study. Heart cannulation and perfusion were performed as described previously [27]. Briefly, isolated hearts were perfused retrogradely with freshly prepared Krebs-Hensleit buffer, pH 7.35 to 7.45 at 37.0 ± 0.5°C and gassed with CO₂ (5%) and O₂ (95%). Pacing electrodes were placed on RA appendage to keep the heart beating at physiological rat heart rate. Regional ischemia was induced by occluding left anterior descending (LAD) coronary artery for 30 min. Preload was kept constant at 6 mmHg under basal controlled conditions and perfusion pressure (PP) at 50 mmHg throughout the experimental procedure in all protocols. The perfusion pressure was measured downstream from a branch of the aortic cannula using a “statham pressure transducer” (P23 Db). Constant PP was ensured electronically by means of the perfusion assembly (“Module PPCM type 671 (Hugo Sachs Elektronik- Harvard ApparatusGmbH, Germany”), an effective system for the accurate adjustment of PP between 5 mmHg to 150 mmHg with ± 1 mmHg accuracy level.

Study Protocol and Study Groups

Hearts were subdivided into 10 groups (n = 8 per group). Hearts were subjected to ischemia followed by reperfusion (control) or ischemia followed by LV pacing (PPC) in the presence or absence of target specific drug (Fig 1). Ischemia (30 min) was produced by LAD coronary
artery occlusion. The LAD coronary artery was encircled by a snare at approximately 0.5 cm below the atrioventricular groove, and a small rigid plastic tube was positioned between the heart and the snare to ensure complete occlusion of the coronary artery. Hearts were then reperfused for 30 min. In hearts subjected to PPC, one pacing electrode was fixed to the posterior basal LV wall and connected to a pacemaker set to the required pacing frequency. PPC involved three alternating RA and LV pacing episodes, 30 s each. The on and off cycles of pacing were selected based on a previous study by our group [10] and were confirmed by a pilot study (data not shown).

Data Collection and Processing

LV function was evaluated by the assessment of LV end diastolic pressure (LVEDP) and LV developed pressure (DPmax) while coronary-vascular dynamics were evaluated by the assessment of the coronary flow (CF) and coronary vascular resistance (CVR). Cardiovascular functions were measured as previously described [27]. Briefly, a water-filled latex balloon was

---

**Fig 1. Schematic representation of the experimental protocols used in the study.** Hearts isolated from Wistar rats were subjected to one of the following protocols (n = 8 hearts per treatment): (A) Unprotected ischemia-reperfusion (control). (B) Ischemia and PPC started immediately at the start of reperfusion. (C) Ischemia and drug dosed 5 min before the start of reperfusion in absence of PPC. (D) Ischemia in presence of PPC and drug dosed 5 min before the start of reperfusion. LV, left ventricle; PPC, pacing postconditioning.

doi:10.1371/journal.pone.0165777.g001
placed and secured in LV cavity. The balloon was attached to a pressure transducer and a "DC-Bridge amplifier (DC-BA)" with a pressure module (DC-BA type 660, Hugo-Sachs Elektronik, Germany) and interfaced to a personal computer for on-line monitoring of DPmax. LV developed pressure was derived from online acquisition of LV end systolic pressure (LVESP) using Max-Min module (Number MMM type 668, Hugo Sachs Elektronik-Harvard Apparatus GmbH, Germany) which has the ability to convert the output from DC bridge amplifier to DPmax by subtracting LVEDP from the LVESP.

Coronary flow was continuously measured using an electromagnetic flow probe attached to the inflow of the aortic cannula interfaced to a personal computer. The continuous monitoring of the CF in ml/min was digitally monitored using software developed by Hugo-Sachs (Hugo-Sachs Elektronik, Germany) specifically for this purpose and was manually verified by timed collection of coronary effluent. The CVR and hemodynamics data were determined every 10 sec using an on-line data acquisition program (Isoheart software V 1.524-S, Hugo-Sachs Elektronik, Germany). By the end of each experiments, hearts were snap frozen in liquid nitrogen then stored in -80°C for further analysis.

Assessment of cardiac damage by TTC staining and cardiac enzyme release

Hearts (n = 4 per group) were collected after 30 min of reperfusion and stored overnight at -20°C. The next day the hearts were sliced to 4–5 pieces from apex to base. The slices were then incubated in 1% 2,3,5-Triphenyl-2H-tetrazolium chloride (TTC) solution in isotonic (pH 7.4) phosphate buffer and then fixed in 4% formaldehyde. The red and pale non stained areas of every slice were indicated manually on the image. The percentage of the infarct size of the LV was calculated for every heart. Quantification of the LV and infarct size was done using ImageJ (Image J, Wayne Rasb and National Institute of Health, USA). Cardiomyocytes injury was evaluated by measuring creatine kinase (CK) and lactate dehydrogenase release in the coronary effluent during the reperfusion period as described previously by Ferrera et al. [28].

Immunoblotting

Left ventricles (n = 4 per group) were homogenized in ice-cold lysis buffer, and the homogenate was centrifuged at 4000 rpm for 10 min. The supernatant was collected, protein content was measured and the samples were aliquoted and stored at -80°C for further analysis. The expression of proteins in question was done as described previously [29]. Equal loading was checked by stripping and reprobing the membrane with Actin antibodies. The levels of total ERK1/2, p38 MAPK and AKT and phosphorylated ERK1/2 (Thr202/Tyr204), phosphorylated p38 MAPK (Thr180/Tyr182) and phosphorylated AKT (Thr308/Ser473) were determined using monoclonal antibodies (Cell Signaling Technology, Inc). Detection was performed with the enhanced chemiluminescence after incubation with a suitable secondary antibody conjugated to horseradish peroxidase (ECL; Cell Signaling Technology). Densitometric analysis was performed using Quantity One software (Biorad).

Data Analysis

Data were expressed as means ± standard error of the mean (SEM). Hemodynamics data were analyzed with One-way analysis of variance (ANOVA) to determine differences between multiple groups. If an analysis of variance showed a significant difference, post hoc analysis with Tukey test was used for further comparisons. P<0.05 was considered statistically significant.
Results

The role of exogenously administered and endogenously produced Ang II in I/R injury and PPC was examined using recombinant Ang II and ACE and chymase enzyme specific inhibitors, respectively. Exogenously administered Ang II did not affect cardiac hemodynamics (Fig 2), infarct size or cardiac enzymes (Fig 3 and Table 1) in hearts subjected to I/R injury or PPC suggesting that exogenous administration of Ang II does not worsen I/R injury nor attenuates PPC mediated protection of isolated rodent hearts.

Fig 2. The role of exogenously administered Ang II and Ang II receptor, AT1, in PPC. Isolated rat heart (n = 8 per group) were subjected to I/R injury with or without PPC. Hearts were then infused with Ang II (100nM) or AT1 antagonist (irbesartan, 10μM) and post-ischemic recovery of cardiac functions were recorded. (A) DPmax, (B): LVEDP, (C) CF and (D) CVR. The data were computed at 30 min reperfusion and are expressed as means ± SEM. DPmax, maximum developed pressure; LVEDP, left ventricular end diastolic pressure; CF, coronary flow; CVR, coronary vascular resistance; Ctr, control; Isch, ischemia; PPC, pacing postconditioning. *P<0.05 compared to respective control. †P<0.05 compared to ischemic period.

doi:10.1371/journal.pone.0165777.g002
In the heart Ang II can be produced locally by ACE-dependent and independent pathways. We therefore tested the involvement of locally produced Ang II in I/R injury and in PPC mediated cardioprotection. The involvement of ACE dependent and chymase mediated intracellular production of Ang II were tested by infusion of captopril or chymostatin at reperfusion, respectively. Myocardial infusion of captopril or chymostatin significantly (P < 0.05) protected the heart against I/R injury (Fig 4) and reduced infarct size and cardiac enzymes (Fig 3 and Table 1). The protective effects of PPC on heart hemodynamics, infarct size and cardiac enzymes (Fig 3 and Table 1) however were not augmented by the administration of captopril or chymostatin (Fig 4). All together this data suggest the possible involvement of ACE and chymase dependent production of Ang II during I/R induced cardiac injury while the lack of an additive effect of captopril and chymostatin to PPC mediated protection may however suggest the existence of a common downstream effector pathway. Locally produced Ang II however does not seem to play a significant role in PPC induced protection.

Detrimental effects of Ang II in the cardiovascular system were shown to be mediated by AT1. We have therefore tested the involvement of AT1 in the observed effects of locally produced Ang II using Ang II receptor blocker, irbesartan. We anticipated that blockage of AT1
would reduce I/R injury and may potentially enhance PPC mediated cardiac protection. To our surprise however, infusion of AT1 receptor antagonist did not protect the heart against I/R injury and interestingly revoked the protective effects of PPC on coronary vascular dynamics (Fig 2), infarct size and cardiac enzymes (Fig 3 and Table 1).

To investigate possible downstream signaling pathways involved in PPC mediated cardiac protection we tested the effect of Ang II, ACE inhibitor, chymase inhibitor or AT1 antagonist in presence or absence PPC on the activation state of signaling mediators of the reperfusion injury salvage kinase (RISK) pathway. Ang II treatment did not affect the basal ratio of phosphorylated to total extracellular regulated kinases 1/2 (ERK1/2) or protein kinase B/Akt during I/R injury neither it blocked enhanced phosphorylation of ERK1/2 and Akt in response to PPC (Fig 5). Captopril and chymostatin however significantly (P<0.05) increased ERK1/2 and Akt phosphorylation during I/R injury, yet did not augment PPC-induced phosphorylation of ERK1/2 and Akt possibly suggesting RISK downstream of a common signaling pathway activated by PPC and by the inhibition of ACE and chymase (Fig 5). Blockade of AT1 did not induce ERK1/2 and Akt phosphorylation during I/R injury, however it completely blocked their activation during PPC (Fig 5). This observation is consistent with the lack of an effect of AT1 blockade on cardiac hemodynamics, infarct size and cardiac enzymes levels during I/R injury and elimination of PPC mediated protection. Finally no changes were observed in the phosphorylation state of p38 MAPK during PPC in the presence or absence of Ang II, captopril, chymostatin and irbesartan (data not shown) suggesting that p38 MAPK is dispensable in PPC mediated protection and in PPC interaction with RAS.

### Discussion

In this study we tested the interaction between ACE-Chymase-Ang II-AT1 and PPC mediated cardiac protection in isolated rodent hearts. The main findings of this study are: (1) systemically infused Ang II does not enhance I/R injury nor abrogate the protective effects of PPC. (2) inhibition of ACE or chymase protects against I/R injury yet does not block or augment PPC mediated protection. (3) blockade of AT1 does not protect against I/R injury yet evokes the protective effects of PPC on coronary hemodynamics, infarct size and cardiac enzymes. (4) the interaction between ACE-chymase-Ang II-AT1 and PPC involves signaling via ERK1/2 and Akt members of the RISK pathway (Fig 6).

### Table 1. Effects of RAS system on the infarct size and heart enzymes levels.

| Treatment          | Infarct size | P value | CK   | P value | LDH   | P value |
|--------------------|--------------|---------|------|---------|-------|---------|
| Control            | 49.39±2.18   | -       | 49.43±1.70 | -       | 33.63±1.23 | -       |
| Pacing at LV       | 21.78±2.81*  | 0.001   | 31.57±1.56* | 0.01    | 14.17±1.47* | 0.001   |
| Ischemia + AT1A    | 50.67±2.92   | 0.3264  | 45.73±2.74 | 0.316   | 31.07±2.28 | 0.379   |
| PPC + AT1A         | 53.00±2.96   | 0.3786  | 40.63±3.89 | 0.107   | 31.27±2.51 | 0.445   |
| Ischemia + ANG II  | 54.94±5.05   | 0.3658  | 45.63±0.98 | 0.126   | 37.33±1.65 | 0.147   |
| PPC + ANG II       | 22.51±1.55*  | 0.001   | 19.17±3.12* | 0.001    | 21.00±1.65* | 0.01     |
| Ischemia + Ch      | 20.00±1.01*  | 0.001   | 23.20±2.91* | 0.001    | 17.00±2.50* | 0.01     |
| PPC + Ch           | 20.21±0.88*  | 0.001   | 26.70±2.91* | 0.01    | 17.17±2.47* | 0.01     |
| Ischemia + Cap     | 23.27±0.83*  | 0.001   | 28.07±2.12* | 0.001    | 15.1±1.63*  | 0.001    |
| PPC + Cap          | 21.96±1.95*  | 0.001   | 25.67±2.56* | 0.01    | 17.20±1.10* | 0.001    |

AT1A, angiotensin receptor 1 antagonist; PPC, pacing postconditioning; ANG II, angiotensin II, Ch, chymostatin; Cap, captopril.

*P<0.05 compared to respective controls.

doi:10.1371/journal.pone.0165777.t001
The RAS is a key regulatory system of cardiovascular physiology in which Ang II is a major effector peptide [13]. Ang II can be produced systemically via ACE dependent pathway or locally via ACE dependent or independent enzymes [20, 21]. The exact role of RAS in I/R induced injury and PPC mediated ex vivo cardioprotection is however not clearly understood. Local production of Ang II by ACE and chymase is stimulated by stress and ischemic insult [22] and has been implicated in post ischemic cardiac remodeling [30]. Increasing body of evidence indicates the presence of ACE and supports its role in the intracellular production of Ang II in cardiomyocytes [31, 32], heart failure [33] and myocardial infarction [34]. Enhanced chymase mediated intracellular production of Ang II was reported in the vasculature, isolated cardiomyocytes [35], atherosclerotic lesions [36] and infarcted myocardium [22]. The role of

![Graph showing effects of ACE inhibitor and chymase inhibitor on cardiac functions](image-url)

Fig 4. The role endogenously produced Ang II in PPC mediated cardiac protection. Isolated rat hearts (n = 8 per group) were subjected to I/R injury and PPC in the presence or absence of ACE inhibitor (captopril, 100μM) or chymase inhibitor (chymostatin, 100nM). Post-ischemic recovery of cardiac functions were recorded. (A) DPmax, (B) LVEDP, (C) CF and (D) CVR. The data were computed at 30 min reperfusion and are expressed as means ± SEM. DPmax, maximum developed pressure; LVEDP, left ventricular end diastolic pressure; CF, coronary flow; CVR, coronary vascular resistance; Ctr, control; Isch, ischemia; PPC, pacing postconditioning.*P<0.05 compared to respective control, †P<0.05 compared to ischemic period.

doi:10.1371/journal.pone.0165777.g004
ACE or chymase stimulated production of Ang II in postconditioning remains however to be characterized. In this study we demonstrate that blockade of ACE or chymase mediated endogenous production of Ang II, by captopril and chymostatin respectively, alleviates I/R injury. Captopril mediated protection could be due to reduced production of endogenous Ang II or reduction in kinins degradation [37, 38]. This finding sheds light on previously undiscovered role of ACE-dependent and ACE-independent (chymase mediated) endogenous production of

**Fig 5. The effect of ACE-Chymase-Ang II-AT1 signaling and PPC on the RISK pathway.** (A) Immunoblotting of P-AKT and (B) P-ERK1/2 expressed relative to total AKT and ERK1/2, respectively. Data is presented as mean ± SEM. Ctr, control; PPC, pacing postconditioning. *P<0.05 compared to the untreated control.

doi:10.1371/journal.pone.0165777.g005
Ang II in I/R injury and highlights the existence of potentially, overlooked, targets in the clinical application of postconditioning. Administration of chymase inhibitors to animal models of atherosclerosis, hypertension and heart failure demonstrated multiple beneficial effects including reduced atherosclerotic plaque development [39], improved LV contractility [40] and attenuated post-MI cardiac remodeling with overall improved survival [4]. Furthermore oral administration of chymase inhibitor reduced cardiac injury in a dog model of I/R injury [7]. It cannot be ruled out however that the protective effects of captopril and chymostatin could due to their indirect effects on other peptides besides Ang II [41, 42]. This possibility however remains to be further investigated.

In the cardiovascular system many of the physiological and pathophysiological effects of Ang II are mediated by AT1 receptors [30]. We therefore tested the role of AT1 in PPC
mediated cardiac protection. Based on our data from captopril or chymostatin treated hearts, we anticipated that inhibition of AT1 will improve the protective effects of PPC. To our surprise however, PPC mediated protection on cardiac hemodynamic and infarct size were lost upon the infusion of AT1 antagonist (Fig 6, Table 1). This may suggest the possible requirement of AT1 signaling in PPC mediated protection of rodent hearts ex vivo. Signaling via AT1 involved G-protein dependent and G-protein independent pathways [22]. While G-protein signaling has been linked to I/R induced damage, G-protein independent signaling was shown to induce cardioprotection [43]. Simultaneous blockade of G-protein coupled signaling and activation of G-protein independent signaling through AT1 receptor protected against I/R induced injury as indicated by reduced infarct size [43]. Another possible explanation to the loss of PPC mediated cardiac protection in the presence of AT1 antagonist could be due to mechanical stretch induced changes in AT1 signaling and/or localization. Mechanical stretch was reported to activate AT1 receptor independent of Ang II [44]. In addition AT1 was reported to undergo a conformational switch in response to mechanical stretch resulting in inverse agonist-induced inactivation [45]. Tension induced thinning of the membrane lipid bilayer has been suggested as a possible mechanism. However the precise mechanism by which mechanical force is transmitted to AT1 remains to be identified [45]. Similar inverse behavior was shown in α2A-adrenergic receptor whereby inverse agonists resulted in a conformational rearrangements in the receptor and subsequent suppression in activity [46]. Thus its plausible to speculate that pacing induced mechanical stretch may alter AT1 mediated signaling whereby the AT1 antagonist (irbesartan) acts as a receptor agonist. However, this possibility remains to be tested.

The RISK is a cascade of kinase that has classically been implicated in cardioprotection. The pathway involves parallel activation of PI3K/Akt and ERK1/2 upon engagement of g-protein coupled receptors or growth factor receptors resulting in inhibition of glycogen synthase kinase 3β and prevention of subsequent opening of mitochondrial permeability transition pores [47]. Activation of RISK family members ERK1/2 and Akt were shown to confer cardioprotection during reperfusion [48] and postconditioning maneuvers [49–51]. Here we show that PPC induced cardiac protection also involves enhanced activation of ERK1/2 and Akt (Fig 5). In contrast however Pipicz and his group have demonstrated that rapid ventricular pacing does not induce ERK1/2 activation [52]. The reason behind this discrepancy is however not clear. Differences in the pacing procedures used could be a possibility. In addition we demonstrate that the activation state of ERK1/2 and Akt is subjected to regulation by RAS during I/R injury and in PPC-induced protection. Consistent with its effects on cardiac hemodynamics, infarct size and cardiac enzymes levels, exogenously infused Ang II did not change the phosphorylation state of ERK1/2 and Akt during I/R injury and PPC. Inhibition of locally synthesized Ang II by the administration of captopril or chymostatin however significantly induced ERK1/2 and Akt phosphorylation during I/R injury yet did not enhance their activation in hearts subjected to PPC. Suggesting the potential involvement of locally produced Ang II in I/R induced injury and the possible convergence of protection induced by blockage of intracellular synthesis of Ang II and PPC into a common downstream signaling pathway that ultimately stimulates ERK1/2 and Akt. Finally blockade of AT1 did not alter the activation state of ERK1/2 or Akt in response to I/R injury. Inhibition of AT1 however significantly reduced the activation of ERK1/2 and Akt in response to PPC. Likewise this data is consistent with the lack of PPC induced cardiac protection in the presence of irbesartan.

Our study provided insight into ACE-Chymase-Ang II-AT1 role in I/R induced injury and PPC mediated cardiac protection. Findings from this study are likely to have a direct impact on our understanding of the physiological role of RAS in I/R injury and on RAS components that could potentially be attractive pharmacological targets. Our data suggests that AT1 antagonist
(irbesartan) offsets the protective effects of PPC. This suggests that hypertensive patients on irbesartan or possibly other AT1 blockers need to be carefully considered in future PPC studies. Henceforth care must be taken when planning studies including this group of patients. Drug interference with postconditioning maneuvers was reported in patients with acute coronary syndrome and was suggested to interfere with postconditioning afforded protection [53], [54]. Our data further suggests that blockade of endogenously synthesized Ang II by captopril or chymostatin post-ischemically might represent a novel pharmacological alternative to PPC for the treatment of myocardial I/R injury as the attained cardioprotection was comparable to that of PPC. The latter finding may have important clinical implications as these drugs are already used in clinical practice and could potentially be safely administered after myocardial infarction. The use of ACE and chymase inhibitors in the treatment of myocardial infarction however needs to be further evaluated at pre-clinical and clinical levels.

Conclusions
In conclusion this study identifies a previously undiscovered role ACE and chymase induced synthesis of endogenous Ang II in mediating I/R cardiac injury and highlights the significance of ACE and chymase blockage as a potential therapeutic target in the treatment of myocardial infarction. It further characterizes a novel role of AT1 in PPC mediated cardiac protection of rodent hearts ex vivo. Finally it demonstrates that the RISK pathway is a downstream target of PPC and ACE-chymase-Ang II-AT1 signaling.

Author Contributions
Conceptualization: FB.
Data curation: FB AA SJ.
Formal analysis: FB AA SJ.
Funding acquisition: FB.
Investigation: FB AA SJ.
Methodology: FB AA SJ.
Project administration: FB.
Resources: FB.
Software: FB AA SJ.
Validation: FB AA.
Writing – original draft: FB AA.
Writing – review & editing: FB AA SJ.

References
1. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis. 2009; 204(2):334–41. Epub 2008/12/17. doi: 10.1016/j.atherosclerosis.2008.10.028 PMID: 19081095.
2. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003; 285(2):H579–88. PMID: 12860564. doi: 10.1152/ajpheart.01064.2002
3. Freixa X, Belleria N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J. 2012; 33(1):103–12. doi: 10.1093/eurheartj/ehr297 PMID: 21846677.

4. Hahn JY, Song YB, Kim EK, Yu CW, Bae JW, Chung WY, et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation. 2013; 128(17):1889–96. doi: 10.1161/CIRCULATIONAHA.113.001690 PMID: 24068776.

5. Limalanathan S, Andersen GO, Abdelnoor M, Hoffmann P, Eritsland J. Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POSTconditioning in ST-Elevation Myocardial Infarction) randomized trial. Journal of the American Heart Association. 2014; 3(2):e000679. doi: 10.1161/JAHA.113.000679 PMID: 24760962; PubMed Central PMCID: PMC4187468.

6. Yetgin T, Magro M, Manintveld OC, Nauta ST, Cheng JM, den Uil CA, et al. Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning. Basic Res Cardiol. 2014; 109(2):403. doi: 10.1007/s00395-014-0403-3 PMID: 24481769; PubMed Central PMCID: PMC3951883.

7. Lonborg JT. Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype? Heart. 2015; 101(20):1612–8. doi: 10.1136/heartjnl-2015-307804 PMID: 26130664.

8. Vanagt WY, Cornelussen RN, Pouлина OP, Blaauw E, Vermeulen K, Cleutjens JP, et al. Pacing-induced dyssynchrony preconditions rabbit myocardium against ischemia/reperfusion injury. Circulation. 2006; 114(1 Suppl):I264–9. PMID: 16820583. doi: 10.1161/CIRCULATIONAHA.105.000893.

9. Babiker FA, Lorenz-Scmidt I, Mokelke E, Vanagt WY, Delhaas T, Waltenberger J, et al. Long-term protection and mechanism of pacing-induced postconditioning in the heart. Basic Res Cardiol. 2010; 105(4):523–33. Epub 2010/03/26. doi: 10.1007/s00395-010-0095-2 PMID: 20336304; PubMed Central PMCID: PMC2862957.

10. Vanagt WY, Cornelussen RN, Baynham TC, Van Hunnik A, Pouлина OP, Babiker F, et al. Pacing-induced dyssynchrony during early reperfusion reduces infarct size. J Am Coll Cardiol. 2007; 49(17):1813–9. PMID: 17466233. doi: 10.1016/j.jacc.2007.01.070.

11. Waltenberger J, Geissmann M, Bekkers SC, Vainer J, van Ommen V, Eerens F, et al. Clinical pacing post-conditioning during revascularization after AMI. JACC Cardiovascular Imaging. 2014; 7(6):620–6. Epub 2014/06/14. doi: 10.1016/j.jcmg.2014.01.017 S1936-878X(14)00242-3 [pii]. PMID: 24925330.

12. Garcia RA, Brown KL, Pavlec RS, Go KV, Covell JW, Villarreal FJ. Abnormal cardiac wall motion and early matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2005; 288(3):H1080–7. doi: 10.1152/ajpheart.00860.2004 PMID: 15486029.

13. Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol. 2005; 37(7):1357–67. Epub 2005/04/19. S1357-2725(05)00032-4 [pii] doi: 10.1016/j.biocel.2005.01.012 PMID: 15832688.

14. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003; 24(3):261–71. doi: 10.1210/er.2003-0001 PMID: 12788798.

15. Daugherty A, Cassis L. Angiotensin II-mediated development of vascular diseases. Trends in cardiovascular medicine. 2004; 14(3):117–20. doi: 10.1016/j.tcm.2004.01.002 PMID: 15121160.

16. Jandeleit-Dahm K, Cooper ME. Hypertension and diabetes: role of the renin-angiotensin system. Endocrinology and metabolism clinics of North America. 2006; 35(3):469–90, vii. doi: 10.1016/j.ecl.2006.06.007 PMID: 16959581.

17. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens. 2012; 21(2):147–56. Epub 2012/01/14. doi: 10.1097/MNH.0b013e32834b25b PMID: 22240440.

18. Abwainy A, Babiker F, Akhtar S, Benter IF. Endogenous angiotensin-(1–7)/Mas receptor/NO pathway mediates the cardioprotective effects of pacing postconditioning. Am J Physiol Heart Circ Physiol. 2016; 310(1):H104–12. doi: 10.1152/ajpheart.00121.2015 PMID: 26519026.

19. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. The American journal of physiology. 1992; 263(4 Pt 1): C851–63. PMID: 1384355.

20. Nishimoto M, Takai S, Sawada Y, Yuda A, Kondo K, Yamada M, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg. 2001; 121(4):729–34. Epub 2001/03/30. S0022-5223(01)18191-2 [pii] doi: 10.1067/mct.2001.112467 PMID: 11279415.
21. Urata H. Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2000; 1(2 Suppl):S35–7. Epub 2000/01/03. 268 [pii] doi: 10.3317/jraas.2000.054 PMID: 17199219.

22. Ihara M, Urata H, Shirai K, Ideishi M, Hoshide F, Suzumiya J, et al. High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology. 2000; 94(4):247–53. 47325. PMID: 11326146. doi: 47325

23. Sharma A, Singh M. Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res. 2000; 41(6):635–40. PMID: 10816332. doi: 10.1006/phrs.1999.0631

24. Schupp M, Janke J, Classen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004; 109(17):2054–7. doi: 10.1161/01.CIR.0000127955.36250.65 PMID: 15117841.

25. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res. 2009; 82(1):40–50. doi: 10.1093/cvr/cvp003 PMID: 19147651.

26. de Oliveira UO, Bello-Kein A, de Oliveira AR, Kuchaski LC, Machado UF, Irigoyen MC, et al. Insulin alone or with captopril: effects on signaling pathways (AKT and AMPK) and oxidative balance after ischemia-reperfusion in isolated hearts. Fundamental & clinical pharmacology. 2012; 26(6):679–89. doi: 10.1111/j.1472-8206.2011.00995.x PMID: 22029532.

27. Babiker FA, Joseph S, Juggi J. The protective effects of 17beta-estradiol against ischemia-reperfusion injury and its effect on pacing postconditioning protection to the heart. J Physiol Biochem. 2014; 70(1):151–62. Epub 2013/09/17. doi: 10.1076/s13105-013-0289-9 PMID: 24037795.

28. Ferrera R, Benhabbouche S, Bopassa JC, Li B, Ovize M. One hour reperfusion is enough to assess function and size effect with TCC staining in Langendorff rat model. Cardiovasc Drugs Ther. 2009; 23(4):327–31. doi: 10.1007/s10557-009-6176-5 PMID: 19466533.

29. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, et al. Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol. 2006; 26(7):1524–30. Epub 2006/04/22. 01.ATV.0000223344.11128.23 [pii] doi: 10.1161/01.ATV.0000223344.11128.23 PMID: 16627800.

30. De Mello WC, Frohlich ED. On the local cardiac renin-angiotensin system. Basic and clinical implications. Peptides. 2011; 32(8):1774–9. doi: 10.1016/j.peptides.2011.06.018 PMID: 21729730.

31. Kumar R, Yong QC, Thomas CM, Baker KM. Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol. 2012; 302(5):R510–7. doi: 10.1152/ajpregu.00512.2011 PMID: 22170614; PubMed Central PMCID: PMC331519.

32. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiacmyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57(12):3297–306. doi: 10.2337/db08-0805 PMID: 18829990; PubMed Central PMCID: PMC2584136.

33. De Mello WC. Further studies on the effect of intracellular angiotensins on heart cell communication: on the role of endogenous angiotensin II. Regulatory peptides. 2003; 115(1):31–6. doi: 12873796.

34. Clausmeyer S, Reinecke A, Farrenkopf R, Unger T, Peters J. Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction. Endocrinology. 2000; 141(8):2963–70. doi: 10.1210/end.141.8.7623 PMID: 10919285.

35. Dell’Italia LJ, Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol. 2002; 17(4):374–9. Epub 2002/08/02. PMID: 12151872.

36. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999; 33(6):1399–405. PMID: 10373223.

37. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res. 2006; 98(7):887–96. doi: 10.1161/01.RES.0000217340.40936.53 PMID: 16614314.

38. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther. 2005; 19(1):77–87. doi: 10.1007/s10557-005-6000-8 PMID: 15883759.

39. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P. The paradigm of postconditioning to protect the heart. Journal of cellular and molecular medicine. 2008; 12(12):435–58. doi: 10.1111/j.1582-4934.2007.00210.x PMID: 18182064; PubMed Central PMCID: PMC3822534.

40. Zablocki D, Sadoshima J. Knocking out angiotensin II in the heart. Current hypertension reports. 2011; 13(2):129–35. Epub 2011/01/15. doi: 10.1007/s11906-011-0180-4 PMID: 21234717; PubMed Central PMCID: PMC3278322.

41. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Current opinion in pharmacology. 2007; 7(2):140–5. doi: 10.1016/j.coph.2006.11.008 PMID: 17303473; PubMed Central PMCID: PMC2930911.
42. Messadi-L aribi E, Griol-Charh bili V, Pizard A, Vincent MP, Heudes D, Meneton P, et al. Tissue kalli-krein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther. 2007; 323(1):210–6. doi: 10.1124/jpet.107.124859 PMID: 17636004.

43. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 2002; 55(4):870–6. PMID: 12176136.

44. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nature cell biology. 2004; 6(6):499–506. doi: 10.1038/ncb1137 PMID: 15146194.

45. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO reports. 2008; 9(2):179–86. doi: 10.1038/sj.embor.7401157 PMID: 18202720; PubMed Central PMCID: PMC2246415.

46. Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ. Molecular basis of inverse agonism in a G protein-coupled receptor. Nature chemical biology. 2005; 1(1):25–8. doi: 10.1038/nchembio705 PMID: 16407989.

47. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008; 118(19):1915–9. Epub 2008/11/05. 118/19/1915 [pii] doi: 10.1161/ CIRCULATIONAHA.108.805242 PMID: 18981312.

48. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004; 61(3):448–60. PMID: 14962476. doi: 10.1016/j.cardiores.2003.09.024

49. Bouhidel JO, Wang P, Li Q, Cai H. Pharmacological postconditioning treatment of myocardial infarction with netrin-1. Front Biosci (Landmark Ed). 2014; 19:566–70. Epub 2014/01/07. 4227 [pii]. PMID: 24389204.

50. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacology & therapeutics. 2007; 116(2):173–91. doi: 10.1016/j.pharmthera.2007.06.005 PMID: 17681609.

51. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004; 95(3):230–2. PMID: 15242972. doi: 10.1161/01.RES.0000138303.76488.fe

52. Pipicz M, Varga ZV, Kupai K, Gaspar R, Kocsis GF, Csonka C, et al. Rapid ventricular pacing-induced postconditioning attenuates reperfusion injury: effects on peroxynitrite, RISK and SAFE pathways. Br J Pharmacol. 2015; 172(14):3472–83. doi: 10.1111/bph.13154 PMID: 25827015.

53. Bice JS, Baxter GF. Postconditioning signalling in the heart: mechanisms and translatability. Br J Pharmacol. 2015; 172(8):1933–46. doi: 10.1111/bph.12976 PMID: 25303373; PubMed Central PMCID: PMC4386973.

54. Ferdinan dy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacological reviews. 2007; 59 (4):418–58. PMID: 18048761. doi: 10.1124/pr.107.06002